New formulation faces the sun

Related tags Personal care Medicine Hygiene Health care

Speciality chemicals company International Specialty Products (ISP)
continues its quest to expand the company's presence in the growing
personal care market segment with the news this week that it has
collaborated with biotech company Vital Health Sciences to sell and
market a range of industry ingredients. First off the mark, Vital
ET, a vitamin E phosphate complex targeted at sun care product
formulations.

International Specialty Products (ISP) continues its quest to expand the company's presence in the growing personal care market segment with the news this week that it has collaborated with biotech company Vital Health Sciences to sell and market a range of industry ingredients. First off the mark, Vital ET, a vitamin E phosphate complex targeted at sun care product formulations.

Under the terms of this latest collaboration, agreed for 10 years, ISP will sell and market into the personal care industry ingredients developed and manufactured by Vital Health​ to all parts of the globe, barring Australia where Vital Health intends to develop its own line of consumer products for the personal care industry.

ISP​ reports that in clinical trials carried out in the US, Vital ET was shown to be effective in both the prevention and amelioration of redness from UV exposure when locally applied to the skin at a level of 1 per cent in an emulsion.

The technology behind the development of this product relies on a process known as phosphorylation which increases the biological effectiveness of compounds by keeping them stable until needed by the body. In addition, the two companies claim that complexation of the phosphorylated compound allows more efficient delivery of the compound to the body either topically or orally.

In a bid to improve its presence in the booming personal care market, ISP recently introduced the Bio-Functional Ingredients platform. Vital ET, together with USP Allantoin, a skin protectant, is the first of several new ingredients in the platform.

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Follow us